Coxsackie adenovirus receptor (CAR) is the primary receptor to which oncolytic adenoviruses have to bind for internalization and viral replication. A total of 171 neuroendocrine lung tumors in form of multitissue arrays have been analyzed resulting in a positivity of 112 cases (65.5%). Immunostaining correlated statistically significant with histopathology and development of recurrence. The subtype small cell lung cancer (SCLC) showed the highest CAR expression (77.6%), moreover the CAR level was correlated to the disease-free survival. Further, high CAR expression level in SCLC cell lines was found in vitro and in vivo when cell lines had been transplanted into immunodeficient mice. A correlation between CAR expression in the primary tumors and metastases development in the tumor model underlined the clinical relevance. Cell lines with high CAR level showed a high infectivity when infected with a replication-deficient adenovirus. Low levels of CAR expression in SCLC could be upregulated with Trichostatin A, a histone deacetylase inhibitor. As a result of the unaltered poor prognosis of SCLC and its high CAR expression it seems to be the perfect candidate for oncolytic therapy. With our clinically relevant tumor model, we show that xenograft experiments are warrant to test the efficiency of oncolytic adenoviral therapy.
INTRODUCTION
Neuroendocrine (NE) tumors of the lung are a subtype of lung cancer, which share certain morphologic, ultrastructural, immunohistochemical and molecular characteristics. Morphologic NE features include organoid nesting, palisading, a trabecular pattern and rosette-like structures, 1 whereas the presence of dense core granules is a typical feature ultrastructurally. Immunohistochemical markers for NE tumors are neuron-specific enolase, the neuronal marker PGP 9.5 (UCHL1), chromogranin, synaptophysin, serotonin and bombesin. The four major categories of morphologically identifiable NE tumors are the low-grade typical carcinoids, intermediate-grade atypical carcinoids, the high-grade large cell NE carcinoma and small cell lung carcinoma (SCLC). SCLC is the most common NE lung cancer accounting for 25 to 30% of all lung cancers. It has the poorest prognosis because of its aggressive growth and early metastatic spread. Systemic polychemotherapy is the therapy of choice; nevertheless the median survival time for limited disease is o20 months 2 and for extensive disease between 7 and 10 months. 3 During the last decades there has been no notable improvement in survival for these patients. The standard of care for both limited disease and extensive disease is a two-drug combined chemotherapy with etoposide and cisplatin. 4 Trials of newer chemotherapy variations could not prove a better effectiveness 5 and new therapeutic options are clearly needed.
Such a new treatment could be an oncolytic adenovirus for systemic therapy. Replication selective adenoviruses like ONYX-015, have been investigated in clinical phase I and II studies of other cancers than SCLC. Several tumor entities such as squamous cell carcinoma of the head and neck, 6 pancreatic cancer, 7 hepato cellular carcinoma 8 and ovarian cancer 9 have been treated with ONYX-015. Nevertheless, nothing is known about the effectiveness of an oncolytic therapy in SCLC. Fundamental requirement for a viral therapy is the binding and subsequent internalization of the virus into the tumor cells. Binding and internalization is mediated by the coxsackie adenovirus receptor (CAR), 10 whose expression level in cancer cells can be highly variable. 11 Low level of expression causes the resistance of an adenoviral infection [12] [13] [14] and even lack of CAR expression in several tumor entities has been detected. 11, 15, 16 As CAR expression is essential for viral infection, tumor entities with a primarily high expression level of CAR are more suited for such a therapy than tumor entities in which the CAR expression levels are low or even absent.
In the normal bronchial epithelium, CAR is localized at the basolateral membrane 17 and as this epithelium is the primary cell population infected by adenoviruses, we hypothesized that CAR is expressed in SCLC cells as well, particularly as it represents the malignant form of stem cells residing in this epithelium. 18 The first aim of our study was to analyze CAR expression in clinical samples of SCLC to investigate if SCLC is a suitable target for oncolytic adenoviral therapy. Second, we analyzed CAR expression in human SCLC cell lines in vitro and grown as primary tumors in immunodeficient mice in vivo in order to choose a suitable animal model for a viral therapy. Third, we verified the infection efficiency of all SCLC cell lines by infecting them with a replication incompetent adenovirus combined with the green fluorescent protein (GFP), which is similar to the clinically used ONYX-015 virus. Finally, we investigated whether CAR expression could be enhanced in SCLC cells in vitro using Trichostatin A (TSA). If so, this would open up the possibility of enhancing the suitability of adenovirus therapy in SCLC patients whose tumor cells do not express CAR sufficiently. 
MATERIALS AND METHODS

Patients and samples
H69
(classic phenotype), 22, 23 H82 (variant phenotype), 19, 23 which were all established from pleural effusions and SW2 (variant phenotype), 22, 24 established from a bone marrow metastasis were propagated in Dulbecco's modification of Eagle's medium (PAA Laboratories, Pasching, Austria) for adenovirus infections. For TSA stimulation, cells were cultivated in RPMI 1640 (Gibco, Scotland, UK). Both media were supplemented with 10% fetal calf serum and 1% penicillin-streptomycin. All cell lines were maintained at 37 1C in a 5% CO 2 atmosphere and 95% humidity.
Histological specimens of SCLC cell lines
Formalin-fixed, paraffin-embedded archival blocks of SCLC of cell lines OH1, OH3, H69, H82 and SW2, grown as primary tumors on immunodeficient pfp/rag2-mice, the corresponding cell pellets and lungs with metastases from primary tumors of the cell lines OH1, OH3 and H69 were cut in 5 mm thick sections, mounted on glass slides and dried overnight at 37 1C in the compartment dryer.
Immunohistochemical staining
The immunohistochemical staining was performed on multitissue arrays of different subsets of NE lung tumors as well as on the experimental human tumors grown in immunodeficient mice. The clinical samples were, after overnight drying, de-paraffinized and rehydrated in xylene and series of graded ethanols and finally placed in Tris-buffered saline (TBS, pH 7.6). The pretreatment was conducted in two steps, first with 0.05% trypsin over 10 min in a 37 1C water bath, followed after rinsing three times in TBS in a steamer (95-99 1C) for 20 min. Sections were cooled for 20 min and then transferred to cold buffer. After 10 min, they were washed three times with TBS. The tissue sections were blocked with 10% normal swine serum/ DAKO Antibody Diluent with Background Reducing Components (DAKO, Carpentaria, CA, USA) for 30 min at room temperature followed by the incubation with CAR (H-300) sc-15405 (Santa Cruz Biotechnology, Heidelberg, Germany), the primary antibody diluted 1:50 overnight at 4 1C. Subsequently sections were rinsed in TBS and incubated in secondary biotinylated swine anti-rabbit immunoglobulin (DakoCytomation, Glostrup, Denmark) diluted 1:200 for 30 min at room temperature. Sections then were washed again in TBS and incubated with an ABC alkaline phosphate kit (Vector Laboratories, Burlingame, CA, USA) for 30 min. After the last rinsing in TBS, sections were transferred into the visualizing mixture containing Naphtol-AS-bisphosphate and hexatozised New Fuchsine for 30 min in the dark. The reaction was stopped under running tap water for 5 min and counterstained with Mayer's hemalaun diluted 1:1 in distilled water for 3 min, blued under running tap water and transferred into distilled water to be mounted with Clarion/Crystal Mount I and II (Biomedia, Foster City, CA, USA).
The xenograft tumors were treated in a similar way. Only the heatinduced pretreatment took place in 10 mM citrate buffer (pH 6.0) and after microwaving three times for 5 min at 500 W, cooling steps followed like described above. In contrast to the first described staining protocol, a different primary antibody was used. Anti-CXADR (rabbit anti-human CXADR prestige antibodies, Sigma-Aldrich, St Louis, MO, USA) diluted 1:200, the same dilution, which was used for the isotype control stained the experimental tumors. All other steps proceeded the same way like described above.
Controls were treated the same way besides using DAKO antibody diluent with background reducing components for the negative and rabbit immunoglobulin normal fraction (DAKO A/S, Glostrup, Denmark) for the isotype control in place of the polyclonal primary antibody against CAR.
Evaluation of immunohistochemistry
The CAR expression level was evaluated under a microscope (Zeiss, Axioplan 2, Gö ttingen, Germany) by two independent observers (TW and US) blinded to the clinical data. If no consensus was achieved in the first instance, cases were discussed until observers' agreement was reached. Staining levels were classified according to staining intensity (negative, low, moderate and intense staining) and percentage (0-100%). We divided Abbreviations: AC, atypical carcinoid; All, all subtypes of neuroendocrine lung tumors; LCNEC, large cell neuroendocrine lung carcinoma; SCLC, small cell lung cancer; TC, typical carcinoid.
the intensity and the percentage into four groups to get a final score by multiplication of both parameters. The frequency graduation was 0: negative staining, 1: 10-49%, 2: 50-79%, 3: 80-100% staining. The intensity was subdivided in 0: no staining/negative control, 1: mild, 2: moderate and 3: intense staining. Finally, the scoring points were classified into 0: for negative, 1: 1-3 scoring points for weak, 2: 4-6 scoring points for moderate and 3: 9 scoring points for strong immunoreactivity for CAR. Specimens were considered positive if 450% of the tumor cells were moderately or intensely stained.
Statistical analysis
The associations of clinicopathologic characteristics and histopathologic types with CAR immunoreactivity were assessed using the w 2 test. Survival curves were constructed using the Kaplan-Meier method and compared by the log-rank test. Cox regression analysis (backward) was used to evaluate the effect of clinicopathologic parameters and CAR expression level as prognostic factors on patients relapse-free and overall survival. A two-tailed Po0.05 was considered statistically significant. Statistical analyses were performed using the software package SPSS for Windows (version 19, SPSS, Chicago, IL, USA).
Virus infection and fluorescence-activated cell scanning
From each cell line of the SCLC, cells were seeded in a six-well plate (300 000 cells per well) and were incubated with a multiplicity of infection of 20 with the virus Ad-GFP for 90 min. The six-well plates were gently shaken every 15 min in a cell culture incubator with 37 1C and 5% CO 2 and 100% humidity. The virus Ad-GFP 25 was diluted with Dulbecco's modified Eagle's medium without fetal calf serum. The infection was stopped by addition of 2 ml full Dulbecco's modified Eagle's medium with 10% fetal calf serum. Cells were reseeded and harvested after 24, 48 and 72 h. After centrifugation, washing twice in phosphate-buffered saline and re-suspending, cells were subjected to FACScan analysis (BDFACSCanto, BD, Franklin Lakes, NJ, USA).
TSA treatment and fluorescence-activated cell scanning A total of 2 000 000 cells from each SCLC cell line were seeded in 2.5 ml medium and 2.5 ml medium added with TSA (Sigma-Aldrich, Steinheim, Germany). The TSA concentrations were 10 nM or 1 mM, respectively. After 6-h incubation in TSA or control-medium, cells were fixed with fixation-buffer (Dulbecco's phosphate-buffered saline Gibco, Invitrogen, Darmstadt, Germany; 1% bovine serum albumin, 0.5% sodium azide and 2% formalin) for 20 min and afterward diluted in 1 ml phosphate-buffered saline stored in the refrigerator overnight. The next day staining of CAR for the fluorescence-activated cell sorting analysis started with re-suspending the cells in a cell dissociation buffer (Invitrogen). Subsequently the cells were incubated for 30 min on ice with the primary antibody diluted 1:50 (anti-CXADR). A normal rabbit serum (DakoCytomation) instead of the antibody was used as control. The incubation was terminated by adding 1 ml fluorescence-activated cell sorting-buffer (phosphate-buffered saline, 1% bovine serum albumin and 0.5% sodium azide) and cells were pelleted by centrifugation. The cells were then incubated with the secondary antibody (swine anti-rabbit) as described above. After washing, incubation with streptavidin ABC (BD Pharmingen, Franklin Lakes, NJ, USA) diluted 1:100 for 30 min in the dark on ice followed. For cell sorting, cells were transferred in fluorescence-activated cell sorting-buffer and analyzed with the FACSCalibur flow cytometer (Becton Dickinson, Heidelberg, Germany).
RESULTS
CAR expression in clinical specimens of NE lung cancers Clinicopathological parameters are summarized in Table 1 . CAR positivity was noted in 112 out of 171 cases (65.5%) of all subtypes of NE lung tumors (Figures 1a-d) . The pattern of CAR distribution was predominantly membranous in all positive cases examined. Immunostaining was significantly associated with the histopathology of the tumor (Po0.000, Figure 1e ). Especially SCLC tissue showed an intense staining (Figure 1a cases were strongly positive, 36.3% moderately positive, 20% weakly positive and only two specimens (2.5%) were CAR negative (see Table 2 ). SCLC was also the subtype of the NE lung tumors with the highest CAR positivity (77.6%). Furthermore, CAR positivity in all NE lung tumors was significantly associated with the development of recurrence of disease (P ¼ 0.035) and a high level of CAR expression correlates with a higher risk of a relapse of disease (Figure 1f) . Positive CAR immunoreactivity did not correlate statistically significant with the rate of metastasis formation (P ¼ 0.073) and also the correlation to disease-free survival missed statistically significance (P ¼ 0.054). But a tendency of CAR expression influencing the prognosis is observable. No statistical significance with other clinicopathological parameters, including gender, age, tumor size or death because of tumor progression was found (all P40.05). In univariate analysis, SCLC cases with moderate and strong CAR immunoreactivity showed a significant inverse correlation to a longer relapse-free survival (P ¼ 0.018; mean relapse-free survival rate 24.94±24.79 month, Kaplan-Meier method; Figure 2d ). In multivariate analysis of all NE tumors, a significant positive correlation between relapse-free survival and grading as well as lymph node metastases, was found (P ¼ 0.037 and P ¼ 0.000028, respectively, Cox regression analysis). Only tumor grade stayed statistically significant concerning overall survival (P ¼ 0.0056, Cox regression analysis). The relative risk for tumor recurrence and death because of tumor progression increased with higher tumor grade (relative risk ¼ 4.23 and relative risk ¼ 7.2, respectively).
CAR expression in NE lung tumor cell lines All investigated human SCLC cell lines grown in culture expressed CAR, although some cell lines had a higher CAR level than others. The cell line with the highest percentage of staining was OH1 with an average 90.0% positive cells and additionally a strong intensity ( þ þ þ ) of CAR-positive cells (Figures 2a-c) (Figure 2e) . Noticeable, the CAR expression level was higher in agar fixed tumor cells than in the corresponding primary tumor tissue. Metastases from OH1, H69 and OH3 cells exhibited a moderate CAR immunoreactivity ( þ þ ). Interestingly, metastases were more intensively stained than their corresponding primary tumors. As a result of the correlation of CAR expression to the survival of patients in SCLC (Figure 2d Upregulation of CAR by TSA pretreatment In order to possibly increase CAR expression for higher infectivity, we analyzed the upregulation of CAR in the SCLC cell lines in culture with a histone deacetylase inhibitor. CAR expression of untreated SCLC cell lines measured by flow cytometry showed a direct correlation to adenoviral infection efficiency (Figures 3a and  b) . The stimulation results showed that in both TSA concentrations an upregulation of CAR expression was notable in all cell lines, whereas the increase in expression with a 10 nM TSA dose was higher than with 1 mM (Figure 3c ). The two cell lines with the lowest CAR expression reacted on treatment with the highest increase in CAR expression. The CAR expression represented by the fluorescent signal intensity of H82 rose from 5.75 FU to 18.08 FU, which is an enhancement of 214.6% as well as H69 with only 3.5 FU, which intensified its staining about 134.7%. The median increment of all cell lines was about 95.3% ( ± 37.5%).
DISCUSSION
CAR is the primary cellular receptor that mediates binding of adenoviruses for their subsequent internalization into the host cells. As a fundamental requirement for an oncolytic adenoviral based gene therapy CAR expression is the most limiting factor and is crucial for the success of such a therapy. To evaluate if oncolytic adenoviruses are an option for SCLC treatment, CAR expression was investigated in a large number of NE lung tumor cases as CAR expression is often downregulated especially in advanced tumor stages (for example, in bladder cancer, prostate cancer and gastric cancer). 14, [27] [28] [29] First all four subtypes of NE lung tumors with different clinical stages were examined. Especially in SCLC a high incidence of CAR Abbreviations: AC, atypical carcinoid; All, all subtypes of neuroendocrine lung tumors; CAR, coxsackie adenovirus receptor; LCNEC, large cell neuroendocrine lung carcinoma; SCLC, small cell lung cancer; TC, typical carcinoid. Moderate and strong CAR immunoreactivity was considered as positive.
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) the metastasis formation in the tumor model (e, f ). Cell lines with higher CAR expression in the primary tumor develop more spontaneous metastases resulting in a poorer prognosis. Statistically significance is indicated at the Kaplan-Meier curve: **Po0.02. expression was found. With 65.5% CAR-positive specimens of all examined NE lung tumors, the prevalence was even higher than in thyroid lesions 30 and endometrial adenomas 31 but not as high as in osteosarcomas with a CAR positivity of 75% 32 although the number of samples in the mentioned study was much lower than in our data.
As opposed to the downregulation of CAR in different tumor entities like ovarian cancer, 33 melanoma, 27 head and neck cancer 28 and bladder cancer, 29 several studies found CAR expression in non-SCLC significantly higher expressed than in normal and paraneoplastic lung tissue. [34] [35] [36] In non-SCLC (squamous cell carcinomas and adenocarcinomas), a CAR positivity of 43% and 70% was found, respectively. 37 Our study confirms the findings of high CAR expression in SCLC 35, 36 with a higher number of investigated cases. For the first time, a statistically significant inverse correlation to relapse-free survival was shown. From the large cohort of 80 primary SCLCs, only 2 (2.5%) showed no immunoreactivity for CAR. In all, 77.6% of all specimens were considered CAR positive, which is even higher than the results for non-SCLC. Based on the findings that CAR is highly expressed in SCLC (average score of 6.18 (77.6%)) in comparison with the other NE lung tumor subtypes (median CAR expression level of 4.43 (50.2%)), one would assume that SCLC is the candidate of choice for an adenoviral oncolytic therapy.
Notably, in addition to SCLC many typical carcinoid tumors exhibit a very high CAR level (68.8%). Furthermore, the significantly correlation to relapse in SCLC, the correlation to the tumor recurrence for all NE tumors and the trend to metastasis formation and shorter disease-free survival shows that CAR might have a crucial role for tumor prognosis. Furthermore, for SCLC an inverse correlation for relapse-free survival was found. Of particular importance is, that in the extended stage of disease expression was still high (median scoring 4.64; 50% for PT3 and PT4), as patients in advanced stages of disease would be the first choice for such a therapy.
Before new therapeutic options can be implemented, preclinical studies have to show the effectiveness and safety of such a new therapy. Therefore, tumor xenografts are of particular importance because they can form the basis for such studies.
To assess whether CAR expression in human malignant lung tissue can be reconstructed in a tumor model for a preclinical therapeutic study, SCLC xenograft tumors were immunohistochemically stained for CAR expression. Several findings showed that the CAR expression is heterogeneous and often low. These observations were made in human bladder cancer, melanoma and prostate cancer cell lines as well as in a non-SCLC xenograft model. [38] [39] [40] [41] In contrast to these reports, staining in the SCLC cell lines was distinctive with an average of CAR-positive staining of 61%. The highest amount of CAR expression revealed OH1 with 90% and an intensity of þ þ þ . Also remarkable were the results of the SCLC metastases and their corresponding primary tumors. Although metastases often expressed CAR intensively, the corresponding primary tumors showed a weaker staining. All cell lines showed a downregulation of CAR in tumor tissue but nevertheless the staining was present. Our results match with findings of other groups in prostate and colon cancer. 42, 43 Nevertheless, the tumor model is particularly suitable for further in vivo studies, because clinical findings show that the increase in CAR expression leads to a more frequent tumor recurrence and a tendency to a more often metastatic spread and as we could show the cell lines with the higher CAR expression have a higher number of metastases. 26 Assuming that the effectiveness of an adenoviral therapy is depending on the amount of CAR expression, the experiments with Ad-GFP, the recombinant replication incompetent human adenovirus type 5, was used to infect the SCLCs cells and to compare the detected CAR level with the rate of infection. We could show that an infection is possible and that CAR expression on each SCLC cell line correlates with the effectiveness of adenoviral infection. High growth rates made the comparability between the cell lines difficult but results of an infection of nearly a third of all cells seemed to be promising especially in regard to a replication incompetent virus. Viral replication of adenoviruses causes a wide spread of infection. A 1000-fold amplification of the amount of viral material is achieved in a single replicative cycle. 44 These results confirm the immunohistochemical staining and provide the basis for xenograft experiments using those viruses.
Furthermore, as the adenovirus is replicating selectively in tumor cells because of gene mutations such as in the tumorsuppressor gene TP53, SCLC is suited for an oncolytic therapy. Wistuba et al. 45 reported p53 mutation in 490% of SCLCs. Also in most of SCLC cell lines abnormalities in the p53 status have been found. [46] [47] [48] For further in vivo studies, the cell line OH1 with its high CAR level would be recommended. It is known as aggressively growing and metastasizing cell line, 26 even if own unpublished and preliminary results show that OH1 only develops micro-metastases in tumor xenograft models, which do not seem to grow further after the primary tumor has been removed. This qualifying factor for the eligibility of the cell line is under further investigation.
In order to increase the infectivity of the oncolytic virus, SCLC cells were treated with an histone deacetylase inhibitor, which had also been used in ovarian and renal cancer 49, 50 as well as in non-SCLC cells. 51 In this study, we could demonstrate an upregulation of CAR expression in all SCLC cell lines with the histone deacetylase inhibitor TSA. The lower effect of the higher concentration of TSA (1 mM) could possibly be a cytotoxic side effect of the higher concentration, which recommends the concentration of 10 nM for further experiments aiming an upregulation of CAR expression on tumor cells. TSA was awarded a great therapeutic potential because of influencing the cell cycle and cell differentiation per initiating the transcription of proapoptotic genes 52 and affect apoptosis, angiogenesis and metastasis of tumor cells. 53 Hence, the average upregulation about 95.32% on a high basic level of CAR in the SCLC cells is a promising indicator of CAR expression before oncolytic therapy.
The results of our clinical studies show that CAR is expressed in a high percentage (77.6%) of SCLCs providing this otherwise untreatable neoplasm an attractive choice for oncolytic therapy. We could furthermore demonstrate that CAR expression is retained in xenograft primary tumors and spontaneous metastases. Our tumor model is particularly appropriate as the SCLC cell lines have a high CAR expression, even in the metastases and most notably it has a clinical relevance. As a result of the high number of cells expressing CAR, the cell line OH1 is the line of choice for such a therapy. More cell lines could be implemented, if the cells were treated with histone deacetylase inhibitor TSA. Beside the CAR upregulation, the drug might serve as an adjuvant for oncolytic therapy because of its proapoptotic effects.
With this study we establish the basis for a promising therapy strategy for SCLC. To establish the oncolytic therapy in vivo xenograft experiments should follow with regard to a clinical benefit.
